$89.25
0.83% yesterday
NYSE, Nov 25, 10:12 pm CET
ISIN
US1011371077
Symbol
BSX

Boston Scientific Stock price

$89.25
+4.52 5.33% 1M
+13.62 18.01% 6M
+31.44 54.39% YTD
+33.56 60.26% 1Y
+48.55 119.29% 3Y
+46.40 108.28% 5Y
+76.39 594.01% 10Y
NYSE, Closing price Mon, Nov 25 2024
-0.75 0.83%
ISIN
US1011371077
Symbol
BSX
Sector

Key metrics

Market capitalization $131.54b
Enterprise Value $140.47b
P/E (TTM) P/E ratio 73.82
EV/FCF (TTM) EV/FCF 65.15
EV/Sales (TTM) EV/Sales 8.83
P/S ratio (TTM) P/S ratio 8.27
P/B ratio (TTM) P/B ratio 6.35
Revenue growth (TTM) Revenue growth 15.65%
Revenue (TTM) Revenue $15.91b
EBIT (operating result TTM) EBIT $2.62b
Free Cash Flow (TTM) Free Cash Flow $2.16b
Cash position $2.57b
EPS (TTM) EPS $1.21
P/E forward 68.08
P/S forward 7.93
EV/Sales forward 8.47
Short interest 0.88%
Show more

Is Boston Scientific a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Boston Scientific Stock Analysis

Unlock Scores for Free

Analyst Opinions

35 Analysts have issued a Boston Scientific forecast:

29x Buy
83%
6x Hold
17%

Analyst Opinions

35 Analysts have issued a Boston Scientific forecast:

Buy
83%
Hold
17%

Financial data from Boston Scientific

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
15,910 15,910
16% 16%
100%
- Direct Costs 5,981 5,981
13% 13%
38%
9,929 9,929
17% 17%
62%
- Selling and Administrative Expenses 4,552 4,552
18% 18%
29%
- Research and Development Expense 1,519 1,519
10% 10%
10%
3,858 3,858
19% 19%
24%
- Depreciation and Amortization 1,235 1,235
5% 5%
8%
EBIT (Operating Income) EBIT 2,623 2,623
27% 27%
16%
Net Profit 1,791 1,791
46% 46%
11%

In millions USD.

Don't miss a Thing! We will send you all news about Boston Scientific directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Boston Scientific Stock News

Neutral
PRNewsWire
one day ago
Acquisition to expand interventional oncology offerings with complementary therapy to treat liver-dominant metastases MARLBOROUGH, Mass. , Nov. 25, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Intera Oncology® Inc., a privately held medical device company that provides the Intera 3000 Hepatic Artery Infusion...
Neutral
PRNewsWire
10 days ago
Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and CHICAGO , Nov. 16, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX™ Left ...
Neutral
Seeking Alpha
11 days ago
Boston Scientific Corporation (NYSE:BSX ) UBS Global Healthcare Conference November 12, 2024 10:15 AM ET Company Participants Jonathan Monson - Senior Vice President, Investor Relations Nick Spadea-Anello - VP & GM of Interventional Cardiology Conference Call Participants Danielle Antalffy - UBS Danielle Antalffy So good morning, everyone. Thanks so much for joining us.
More Boston Scientific News

Company Profile

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Head office United States
CEO Michael Mahoney
Employees 48,000
Founded 1979
Website www.bostonscientific.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today